EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies.

Samarzija, Ivana; Tomljanovic, Marko; Novak Kujundzic, Renata; Troselj, Koraljka Gall

Samarzija, Ivana; Tomljanovic, Marko; Novak Kujundzic, Renata; Troselj, Koraljka Gall.

Afiliação

Samarzija I; Laboratory for Epigenomics, Division of Molecular Medicine, Ruder Boskovic Institute, 10000 Zagreb, Croatia.
Tomljanovic M; Laboratory for Epigenomics, Division of Molecular Medicine, Ruder Boskovic Institute, 10000 Zagreb, Croatia.
Novak Kujundzic R; Laboratory for Epigenomics, Division of Molecular Medicine, Ruder Boskovic Institute, 10000 Zagreb, Croatia.
Troselj KG; Laboratory for Epigenomics, Division of Molecular Medicine, Ruder Boskovic Institute, 10000 Zagreb, Croatia.

Cancers (Basel) ; 14(19)2022 Sep 29.

Article em En | MEDLINE | ID: mdl-36230683

Palavras-chave

EZH2; EZH2 inhibitors; breast cancer; cisplatin; combination therapy; drug resistance; lung cancer; ovarian cancer; targeted anticancer therapy; testicular germ cell tumors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Croácia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google